Presence of endothelial calcium-dependent nitric oxide synthase in breast apocrine metaplasia. by Tschugguel, W. et al.
British Journal of Cancer (1996) 74, 1423-1426
© 1996 Stockton Press All rights reserved 0007-0920/96 $12.00 %
Presence of endothelial calcium-dependent nitric oxide synthase in breast
apocrine metaplasia
W Tschugguell, W Knoglerl, K Czerwenka2, M Mildner3, W Weninger3, R Zeillinger' and
JC Huber1
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Summary Endothelial calcium-dependent nitric oxide (NO) synthase has been shown to be expressed in
human malignant breast tumours, and its presence correlates with tumour grade. Moreover, NO, being
synthesised in breast tumour cells, may increase tumour blood flow and promote angiogenesis. In view of these
aspects, we have assessed the distribution of NO synthase within a series of benign breast tumours using a
monoclonal antibody against human endothelial calcium-dependent NO synthase. Activity was predominantly
localised in apocrine metaplastic cells of fibrocystic disease, as well as in endothelia throughout all tissue
sections. Consistent with previous reports, no endothelial calcium-dependent NO synthase immunoreactivity
was observed in poorly differentiated infiltrating duct carcinoma cells. In conclusion, expression of endothelial
calcium-dependent NO synthase in human breast apocrine metaplasia may be of significance in view of the
NO's vascular effects in benign breast disease.
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Apocrine metaplasia or pink cell change of the breast,
associated with cystic breast epithelium is characterised by
high cylindrical cells with granular eosinophilic cytoplasm
and luminal cytoplasmic projections (Bonser et al., 196L).
For many years apocrine metaplastic cells have been
regarded as having little or no significance in relation to
malignant breast disease. However, based on the findings of
several independent studies (Page et al., 1978; Roberts et al.,
1984; Dixon et al., 1985; Haagensen, 1986; Wellings et al.,
1987), it was concluded that metaplastic apocrine change
reflects a significant epithelial unrest associated with
carcinoma (Wellings et al., 1987).
Since nitric oxide (NO), which is an inorganic free radical
gas, synthesised by a family ofisoenzymes called NO synthases
(Angard, 1994), is known to act not only as a vasorelaxant, but
also as a cytostatic/cytotoxic mediator (F6rstermann et al.,
1994), its role in tumour biology is under thorough
investigation, but up to now remains poorly understood.
Thomsen et al. (1994) recently reported endothelial
calcium-dependent NO synthase (eNOS) activity in human
gynaecological neoplasms, and its presence seems to correlate
inversely with the differentiation of the tumour. In contrast,
the same investigators could not find any activity in breast
tumour cells, as was demonstrated by immunohistochemistry,
whereas tumour-infiltrating macrophages, endothelial and
myoepithelial cells were immunoreactive with a polyclonal
antiserum to NO synthase (Thomsen et al., 1995).
As it was suggested that NO may not only cause tumour
cell cytostasis/cytotoxicity but may also increase tumour
blood flow (Andrade et al., 1992) and promote angiogenesis
(Jenkins et al., 1995) we designed this study to determine if
apocrine metaplastic change in benign breast disease is
associated with the presence of immunohistochemically
detectable eNOS.
Materials and methods
Immunohistochemistry
The staining reactions were performed on frozen sections
of 30 samples of breast tissue. Of these samples, 21 were
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fibrocystic disease, four fibroadenoma, and five were
poorly differentiated ductal carcinoma. For immunohisto-
chemistry, a monoclonal anti-eNOS antibody was used at
a concentration of 2.5 pg ml-1 (Transduction Laboratories,
Lexington, KY, USA). Specificity of the staining for eNOS
was evident from its elimination by preabsorption with the
eNOS peptide and the absence of staining with preimmune
serum as was recently described (Dinerman et al., 1994).
For the immunodetection, a high-performance biotin-
streptavidin detection system was used (Bio Genex, San
Ramon, CA, USA). Vascular endothelial cells in the
samples were used as the positive control; a non-immune
serum was used for the negative control. For the
chromogen reactions, aminoethylcarbazol, which forms a
brown colour, was used with blocking reagents being
included. The sections were finally counterstained with
Mayer's haematoxylin and mounted with an aqueous
medium.
An additional control to exclude cross-reactivity of the
eNOS antibody with n (neuronal) NOS was recently
described by performing eNOS and nNOS immunostaining
on human cerebral arteries (Dinerman et al., 1994). eNOS
immunoreactivity was prominent in the endothelial cell layer
of the middle cerebral artery but not in the adventitia,
whereas nNOS immunoreactivity was confined to nerve fibres
of the adventitia but not vascular endothelium (Dinerman et
al., 1994).
Histochemistry
For NADPH -diaphorase stains the method by Hope and
Vincent (1989) was slightly modified for titration and
subsequent quantification of the NADPH-diaphorase
activity. Five 10-pm-thick sections were cut from additional
three frozen samples of apocrine metaplasia within a
fibrocystic disease and were mounted on glass slides.
Increasing NADPH-diaphorase activity was identified by
incubating the slides with 50 mM Tris-buffered saline
(pH 7.5) containing 2, 1, 0.5 or 0.25 mM NADPH (Sigma,
St Louis, MO, USA), 0.5 mM nitroblue tetrazolium (NBT)
and 0.2% Triton X-100 at 37°C for 30 min. Control
sections were exposed to the staining solution without
NADPH.
All the slides were randomised and coded and then
examined and assessed for the immunohistochemical and
histochemical staining independently by two observers (WT
and KC).Endothelial calcium dependent NO synthase in breast apocrine metaplasia
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Western blotting analysis
To exclude eNOS antibody cross-reactivity with i (inducible)
NOS, Western blot analysis using the anti-eNOS antibody
with 15 pg total cell lysate from mouse macrophages
(Transduction Laboratories), treated with interferon gamma
(IFN-y) and lipopolysaccharide (LPS) for 12 h, was
performed. The lysate was heated at 100°C for 5 min. The
whole tissue lysate, which contained 15 pg of protein, was
subjected to sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE) (7.5% gradient). The separated
proteins were electrophoretically transfered to membranes,
then incubated with the eNOS antibody for 1 h. The bound
antibody was detected using a chemoluminescent detection
kit (ECL Western blotting detection system, Amersham,
Arlington Heights, IL, USA), according to the manufac-
turer's instructions. No appropriately sized protein was
detectable (data not shown).
Results
We used a monoclonal antibody to eNOS to identify and
localise it in our sections. Of the 25 benign breast disease
tissue blocks studied, four specimens with fibroadenoma were
negative for specific staining (results not shown), whereas the
remaining 21 showed the following typical staining char-
acteristics agreed upon by both the observers. Apocrine
metaplastic change was consistently associated with the
strongest intensity of staining (Figure 1) in all of the 21
specimens, and the reaction was predominantly localised
Figure 3 Localisation of NO synthase in endothelial cells within
an infiltrating duct carcinoma, poorly differentiated (bar=20gm).
Figure 1 Mammary cyst with immunostaining of apocrine
metaplastic cells within a benign breast cyst (bar=50,um).
Figure 2 Staining of endothelial cells in a fibrocystic breast
disease (bar=20 pm).
Figure 4 NADPH-diaphorase activity in apocrine metaplastic
and adjacent endothelial cells within a benign breast cyst
(bar=20 um), using (a) 1 mM NADPH and (b) 0.25mM
NADPH. (c) Lack of staining by incubation without NADPH.
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-within the cell cytoplasm. Flattened cyst epithelium showed
no specific staining in all of the cases studied. Morphologi-
cally normal lobules, ducts, blunt ducts and adenosis also
gave no immunoreactivity. Background staining was not
visible in the majority of the cases, although non-specific
artefacts that were interpreted as drying artefacts could be
observed in some of the sections. In addition, immunolabel-
ling of vascular endothelial cells was widespread throughout
all tissue sections (Figure 2). The labelling of these cells was
just as evident as that observed in apocrine metaplastic cells.
No immunolabelling was observed in breast tumour cells
of poorly differentiated, infiltrating duct carcinomas (five
specimens), whereas the endothelial cells of small tumour
vessels and capillaries were intensely immunostained (Figure
3). A control section proved that there was no specific
immunostaining in the absence of the eNOS antibody (results
not shown).
To confirm the presence of NOS activity (Hope and
Vincent, 1989) in apocrine metaplastic cells, NADPH-
diaphorase stains with increasing concentrations of NADPH
were done on frozen sections of fibrocystic disease of the
breast. In this NADPH-dependent reaction, NBT is reduced
to the water-insoluble dye, NBT formazan. The reaction does
not distinguish among the various isoforms of NOS.
Reaction product was identified in both apocrine metaplastic
cells and endothelial cells at 2, 1 (Figure 4a) and 0.5 mM
NADPH. At a concentration of 0.25 mM NADPH, reaction
product was observed in apocrine metaplasia, but not in
endothelium throughout all samples (Figure 4b).
Discussion
In this study we have extended our previous observations,
whereby we identified eNOS in several breast cancer cell lines
(Zeillinger et al., 1996). We have now mapped immunohis-
tochemically the distribution of this NO synthase isoform
using a monoclonal antibody for detection in frozen sections
of benign breast disease and ductal carcinoma of the breast.
Moreover, we used NADPH-diaphorase staining to confirm
the presence of enzymatic NOS activity in apocrine
metaplastic cells.
Our results indicate for the first time that eNOS is
consistently demonstrable in histologically definable apocrine
metaplastic cells found within benign breast disease. The
specific eNOS immunostaining was also found to have a high
regularity in vascular endothelial cells throughout all speci-
mens, which is consistent with the fact that this NO synthase
isoform was first detected in endothelial cells. For quantifica-
tion of biochemical enzyme activity NADPH-diaphorase
staining was compared between apocrine metaplastic and
endothelial cells by incubating additional sections with
increasing concentrations of NADPH. Both cell types were
particularly prominent sites of eNOS protein. Whereas
NADPH-diaphorase activity in endothelial cells was
predictable, the stronger staining pattern in apocrine
metaplastic cells compared with endothelial cells was
unexpected. This might reflect either stronger eNOS activity
or additional activity in apocrine metaplasia as a result of co-
expression of the other NOS isoenzymes, but remains to be
explored further.
Haagensen (1991) suggested three possible roles for
apocrine metaplasia. First, apocrine metaplasia may be a
precursor to malignant transformation. The second possibi-
lity is'that it reflects a response to the same stimulus that can
also induce carcinoma. Finally, these changes may have a
higher propensity for malignant changes.
Apocrine metaplastic cells are also associated with a
strong immunostaining for prolactin (Kumar et al., 1987).
Moreover, this hormone was also found with a high
regularity in breast cancer specimens and, thus, led to the
hypothesis that metaplastic cells may be of significance in
view of the hormone's known growth-stimulating effect on
the breast epithelium (Kumar et al., 1987).
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In gynaecological cancer tissue (ovarian, endometrial and
mixed mesodermal tumours), the presence of eNOS was
shown to correlate inversely with the differentiation of the
tumour (Thomsen et al., 1994). Its activity was significantly
higher in tissue explants of poorly differentiated compared
with moderately differentiated ovarian cancers (Thomsen et
al., 1994). Unexpectedly, the same investigators reported
lack of any NO synthase immunolabelling in breast tumour
cells, whereas tumour-infiltrating macrophages, myoepithe-
lial cells and endothelial cells of tumour vasculature were
intensely immunostained (Thomsen et al., 1995). We have
already demonstrated that several human breast cancer cell
lines express eNOS mRNA, although in much lower
amounts compared with cultured human umbilical vein
endothelial cells (Zeillinger et al., 1996). This eNOS
expression strongly correlated with the oestrogen receptor
status of these lines. Cell lines that did not express the
oestrogen receptor mRNA did not express NO synthase
mRNA. Thus, it was hypothesised that oestradiol-perhaps
in connection with an up-regulation of the oestrogen
receptor-may be a strong enhancer for NO release in
breast tumour cells (Zeillinger et al., 1996). The discrepancy
between both studies (Zeillinger et al., 1996; Thomsen et
al., 1995) could be explained methodologically: it may be a
result of different sensitivity of the detection method by
polymerase chain reaction on the one hand (Zeillinger et
al., 1995), and immunohistochemistry (Thomsen et al.,
1995) on the other hand. This implies that breast cancer
cells express the eNOS protein at a much lower level than
in apocrine metaplastic cells; levels that would probably be
irrelevant in a tumour in which there are other abundant
sources of NO generation, such as macrophages and
endothelial cells.
In addition, results from three specimens ofinvasive ductal
carcinoma that were immunohistochemically stained with a
monoclonal eNOS antibody (Figure 3) were consistent with
those obtained by Thomsen et al. (1995).
However, one can hypothesise that the expression of NO
synthase in tumour-infiltrating macrophages would contri-
bute to the cytotoxic effect of NO on tumour cells, whereas
expression in vascular endothelial and myoepithelial cells
may also increase tumour blood flow and promote
angiogenesis (Weidner et al., 1992). Thomsen et al. (1995)
concluded that a balance in favour of the vascular effects
may explain the positive correlation between NO biosynth-
esis and grade of malignancy. Thus, it was suggested that
NO may have a dual pro- and anti-tumour action (Jenkins
et al., 1995). By considering NO's vascular effects and the
proposal that the free radical NO may also act as a mutagen
(Wink et al., 1991; Zeillinger et al., 1996), we conducted our
study to examine its expression in apocrine metaplastic cells
that demonstrate a strong association with an increased
breast cancer risk (Page et al., 1978; Roberts et al., 1984;
Wellings et al., 1987).
eNOS immunolabelling was detectable in apocrine
metaplasia, with intense staining similar to that of
endothelial cells (Figures 1 and 2). If this apocrine
metaplastic cell is viewed as a preneoplastic cell, a
morphogenetical relationship between apocrine metaplastic
cells and neoplastic breast cancer cells could be suggested.
In conclusion, human breast apocrine metaplasia that was
shown to be associated with an increased breast cancer risk
expresses endothelial calcium-dependent NO synthase. This
may be of significance in view of the NO's vascular effects in
benign breast disease.
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